Michael J. Campa, Ph.D., B.A.

  • Associate Professor of Radiology
  • Research
Address Duke University Medical Sciences Research Building,
Room 121
203 Research Drive
DUMC Box 2610

Durham, NC 27710
Telephone 919-684-5243
Fax 919-684-3269
  • Ph.D., University of Florida, 1989
  • B.A., University of South Florida, 1979
Research Interests There is longstanding evidence that invasive lung cancer is the end result of a multi-step process in which progressive molecular changes herald and accompany cytomorphologic changes. Our knowledge of these molecular events and the specific markers associated with the evolution from initiation to invasion is only partial. A number of specific biomarkers involved in oncogene activation or inactivation of tumor suppressor genes have been identified, but no single marker to date has been shown to have sufficient sensitivity, specificity, and predictive value to stratify all individuals. More likely, panels of markers will require development to best characterize the molecular profiles of susceptible individuals.

Our laboratory is engaged in studies designed to identify novel biomarkers of cancer. We have identified several serum proteins that, when taken together, may signify the presence of cancer. In addition, some of these biomarkers are associated with disease outcome. Hence, the have the potential to predict the course of the disease and help determine the most effective therapeutic strategy.

A different, but related, area of interest of our laboratory is the development of novel antibody-based ligands against cancer-specific molecules for use as non-invasive diagnostic imaging agents. The primary method that we use for identifying these novel ligands is by screening phage-displayed antibody libraries. We constructed the libraries using mRNA isolated from peripheral blood lymphocytes from a llama that had been immunized with various proteins and cell lines. We chose the llama as a source of antibody because they possess a particular type of IgG consisting of only heavy chain. By cloning only the antigen-binding portion of these heavy chain-only antibodies into the library, we were able to decrease the size of the resulting binding moiety by a factor of 10 compared to full-length heavy- and light-chain antibodies. Due to their small size, these so-called nanobodies should be able to penetrate tumors much more quickly than conventional IgG-based antibodies.
  • Campa MJ, Moody MA, Zhang R, Liao HX, Gottlin EB, Patz EF Jr. Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. doi: 10.1007/s00262-015-1787-0. 2016 Feb;65(2):171-80 Abstract
  • Campa MJ, Gottlin EB, Bushey RT, Patz EF Jr. Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. doi: 10.1158/2326-6066.CIR-15-0122. 2015 Dec;3(12):1325-32 Abstract
  • Patz EF Jr, Campa MJ, Gottlin EB, Trotter PR, Herndon JE 2nd, Kafader D, Grant RP, Eisenberg M. Biomarkers to help guide management of patients with pulmonary nodules. doi: 10.1164/rccm.201210-1760OC. 2013 Aug 15;188(4):461-5 Abstract
  • Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF Jr. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). doi: 10.1002/cncr.26270. 2012 Jan 15;118(2):571-8 Abstract
  • Gottlin EB, Bentley RC, Campa MJ, Pisetsky DS, Herndon JE 2nd, Patz EF Jr. The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. doi: 10.1097/JTO.0b013e3182217bec. 2011 Oct;6(10):1687-90 Abstract
  • Dearmond PD, West GM, Anbalagan V, Campa MJ, Patz EF Jr, Fitzgerald MC. Discovery of novel cyclophilin A ligands using an H/D exchange- and mass spectrometry-based strategy. doi: 10.1177/1087057110382775. 2010 Oct;15(9):1051-62 Abstract
  • Amornsiripanitch N, Hong S, Campa MJ, Frank MM, Gottlin EB, Patz EF Jr. Complement factor H autoantibodies are associated with early stage NSCLC. doi: 10.1158/1078-0432.CCR-10-0321. 2010 Jun 15;16(12):3226-31 Abstract
  • Hopper ED, Pittman AM, Tucker CL, Campa MJ, Patz EF Jr, Fitzgerald MC. Hydrogen/deuterium exchange- and protease digestion-based screening assay for protein-ligand binding detection. doi: 10.1021/ac900854t. 2009 Aug 15;81(16):6860-7 Abstract
  • Gottlin EB, Xiangrong Guan, Pegram C, Cannedy A, Campa MJ, Patz EF Jr. Isolation of novel EGFR-specific VHH domains. doi: 10.1177/1087057108327064. 2009 Jan;14(1):77-85 Abstract
  • Hopper ED, Roulhac PL, Campa MJ, Patz EF Jr, Fitzgerald MC. Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection. doi: 10.1016/j.jasms.2008.06.007. 2008 Sep;19(9):1303-11 Abstract
  • Patz EF Jr, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR, Herndon JE 2nd. Panel of serum biomarkers for the diagnosis of lung cancer. 2007 Dec 10;25(35):5578-83 Abstract
  • Hoagland LF 4th, Campa MJ, Gottlin EB, Herndon JE 2nd, Patz EF Jr. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. 2007 Nov 15;110(10):2260-8 Abstract
  • Petersen RP, Campa MJ, Sperlazza J, Conlon D, Joshi MB, Harpole DH Jr, Patz EF Jr. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. 2006 Dec 15;107(12):2866-72 Abstract
  • Howard BA, Furumai R, Campa MJ, Rabbani ZN, Vujaskovic Z, Wang XF, Patz EF Jr. Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. 2005 Oct 1;65(19):8853-60 Abstract
  • Lin SM, Haney RP, Campa MJ, Fitzgerald MC, Patz EF. Characterising phase variations in MALDI-TOF data and correcting them by peak alignment. 2005;1:32-40. Abstract
  • Howard BA, Zheng Z, Campa MJ, Wang MZ, Sharma A, Haura E, Herndon JE 2nd, Fitzgerald MC, Bepler G, Patz EF Jr. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. 2004 Dec;46(3):313-23 Abstract
  • Suber RL, Flanders VL, Campa MJ, Patz EF Jr. Accentuation of differentially expressed proteins using phage technology. 2004 Oct 15;333(2):351-7 Abstract
  • Wang MZ, Shetty JT, Howard BA, Campa MJ, Patz EF Jr, Fitzgerald MC. Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. 2004 Aug 1;76(15):4343-8 Abstract
  • Khan N, Cromer CJ, Campa M, Patz EF Jr. Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. 2004 Jul 15;101(2):379-84 Abstract
  • Campa MJ, Glickman JF, Yamamoto K, Chang KJ. The antibiotic azatyrosine suppresses progesterone or [Val12]p21 Ha-ras/insulin-like growth factor I-induced germinal vesicle breakdown and tyrosine phosphorylation of Xenopus mitogen-activated protein kinase in oocytes. 1992 Aug 15;89(16):7654-8. Abstract
  • Campa MJ, Chang KJ, Molina y Vedia L, Reep BR, Lapetina EG. Inhibition of ras-induced germinal vesicle breakdown in Xenopus oocytes by rap-1B. 1991 Jan 15;174(1):1-5. Abstract
  • Tarnuzzer RW, Campa MJ, Qian NX, Englesberg E, Kilberg MS. Expression of the mammalian system A neutral amino acid transporter in Xenopus oocytes. 1990 Aug 15;265(23):13914-7. Abstract
  • Campa MJ, Kilberg MS. Characterization of neutral and cationic amino acid transport in Xenopus oocytes. 1989 Dec;141(3):645-52 Abstract
  • Bushey RT, Moody MA, Nicely NL, Haynes BF, Munir Alam SM, Keir ST, Bentley RC, Choudhury KR, Gottlin EB, Campa MJ, Liao H-X and Edward F. Patz, Jr. (2016) A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. Cell Reports 15: 1-9.